Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$270K
Filings
10
Firms Hired
1
Active Period
2021–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Mainstreaming Addiction Treatment Act of 2021
2022 · fourth_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 1384
TREATS Act
2022 · fourth_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 1647
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 2617
Restoring Hope for Mental Health and Well-Being Act of 2022
2022 · fourth_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 7666
Medicaid Reentry Act of 2021
2022 · fourth_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 955
Substance Use Prevention, Treatment, and Recovery Act
2022 · fourth_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: S. 4301
Mainstreaming Addiction Treatment Act of 2021
2022 · fourth_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: S. 445
NOPAIN Act
2022 · fourth_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: S. 586
Mainstreaming Addiction Treatment Act of 2021
2022 · third_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 1384
Restoring Hope for Mental Health and Well-Being Act of 2022
2022 · third_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 7666
Substance Use Prevention, Treatment, and Recovery Act
2022 · third_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: S. 4301
Mainstreaming Addiction Treatment Act of 2021
2022 · third_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Client expense: $10,000 · Firm income: —
Matched citations: S. 445
Mainstreaming Addiction Treatment Act of 2021
2022 · second_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 1384
Restoring Hope for Mental Health and Well-Being Act of 2022
2022 · second_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Client expense: $10,000 · Firm income: —
Matched citations: H.R. 7666
Substance Use Prevention, Treatment, and Recovery Act
2022 · second_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Client expense: $10,000 · Firm income: —
Matched citations: S. 4301
Mainstreaming Addiction Treatment Act of 2021
2022 · second_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Client expense: $10,000 · Firm income: —
Matched citations: S. 445
Coordinating Substance Use and Homelessness Care Act of 2022
2022 · second_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Client expense: $10,000 · Firm income: —
Matched citations: S. 4482
Mainstreaming Addiction Treatment Act of 2021
2022 · first_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; Reducing Barriers to Substance Use Treatment Act, All Provisions (bill has not been reintroduced yet); U.S. Department of Health and Human Services, Overdose Prevention Strategy, All Provisions; Enforcement of Pharmacies and Wholesalers Providing Buprenorphine for Opioid Use Disorder.
Client expense: $40,000 · Firm income: —
Matched citations: H.R. 1384
Mainstreaming Addiction Treatment Act of 2021
2022 · first_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; Reducing Barriers to Substance Use Treatment Act, All Provisions (bill has not been reintroduced yet); U.S. Department of Health and Human Services, Overdose Prevention Strategy, All Provisions; Enforcement of Pharmacies and Wholesalers Providing Buprenorphine for Opioid Use Disorder.
Client expense: $40,000 · Firm income: —
Matched citations: S. 445
Mainstreaming Addiction Treatment Act of 2021
2021 · first_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
Client expense: — · Firm income: —
Matched citations: H.R.1384
STOP Fentanyl Act of 2021
2021 · first_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
Client expense: — · Firm income: —
Matched citations: H.R.2366
STOP Stigma Act
2021 · first_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
Client expense: — · Firm income: —
Matched citations: H.R.4244
STOP Fentanyl Act of 2021
2021 · first_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
Client expense: — · Firm income: —
Matched citations: S.1457
Mainstreaming Addiction Treatment Act of 2021
2021 · first_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
Client expense: — · Firm income: —
Matched citations: S.445
Mainstreaming Addiction Treatment Act of 2021
2021 · fourth_quarter · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OVERDOSE PREVENTION STRATEGY, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Client expense: $30,000 · Firm income: —
Matched citations: H.R.1384
Source: Senate LDA